It’s good to throw another heavy pound at 10 times of big bull stocks.
Andon Health Co.Ltd(002432) it was announced before trading on January 14 that its U.S. subsidiary signed another major contract for daily operation, with an amount of 8.1 billion yuan.
Affected by this, Andon Health Co.Ltd(002432) rose again in the morning. As of the morning closing, the share price was reported at 75.28 yuan / share, with a market value of 36 billion yuan.
heavy positive cash
Before trading on January 14, Andon Health Co.Ltd(002432) announced that the U.S. subsidiary and the U.S. ACC (U.S. Army contract management headquarters) signed a procurement contract on January 13, 2022 local time to sell ihealth kit products to them. The total contract price tax was $1.275 billion (including freight), about RMB 8.102 billion, more than 50% of the company’s audited main business revenue in 2020. The contract was signed and came into force on January 13, 2022 local time.
Since the disclosure on November 7, 2021 that covid-19 antigen self-test kit, a US subsidiary, was authorized by FDA for emergency use, Andon Health Co.Ltd(002432) has continuously released positive results. On the evening of January 12, the company announced that its U.S. subsidiaries had received purchase orders and contracts for ihealth kits from New York and Massachusetts, with a cumulative amount of more than 2.1 billion yuan.
Affected by the continued positive impact, in the 48 trading days from November 7, 2021 to January 13, 2022, Andon Health Co.Ltd(002432) share price rose by 26 limits, with a cumulative increase of 1035%. According to choice data, this is the first stock (including new shares) with a cumulative increase of more than 10 times since November 2021. During the period, the company issued 9 share price change announcements and received 4 exchange attention letters and 1 supervision letter.
Since November 2021, A-Shares have risen by the top 20 in the list
Source: China stock market news choice, as of January 13
It is worth noting that Andon Health Co.Ltd(002432) announced on January 13 that the company has completed the grant registration of stock option incentive plan in 2021, granted 7.37 million shares to 353 incentive objects, and the exercise price is 6.49 yuan / share. Incentive objects can start exercising after 16 months. If the stock price of Andon Health Co.Ltd(002432) is still above the current level when the incentive object exercises in the future, it will achieve more than 10 times the income.
Although the above options have not yet expired, the company’s 2020 equity incentive plan has entered the first exercise period, and the vesting period is from October 25, 2021 to October 19, 2022. There are 187 incentive objects who meet the exercise conditions, the number of exercisable options is 3.047 million, and the exercise price is 11.53 yuan / share. If the right is exercised at present, the cumulative floating profit will reach 194 million yuan and the per capita income will be 1.038 million yuan.
covid-19 detection plate continued to strengthen
Since the end of December 2021, covid-19 detection plate has continued to strengthen. In the morning trading on January 14, Andon Health Co.Ltd(002432) , Hangzhou Alltest Biotech Co.Ltd(688606) rose one after another, and Zhejiang Orient Gene Biotech Co.Ltd(688298) , Asahi biology, Beijing Hotgen Biotech Co.Ltd(688068) rose by more than 10%.
Xinhua News Agency previously reported that the U.S. government announced on January 4 that it was about to sign 500 million procurement contracts for covid-19 virus rapid detection boxes.
So far, covid-19 antigen self-test reagent products of Andon Health Co.Ltd(002432) , Aikang biology and Zhejiang Orient Gene Biotech Co.Ltd(688298) have been authorized by FDA for emergency use. Companies such as Medicalsystem Biotechnology Co.Ltd(300439) , Hangzhou Biotest Biotech Co.Ltd(688767) , Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) are also stepping up their layout.
In response to investors’ questions on the interactive platform, Medicalsystem Biotechnology Co.Ltd(300439) , Hangzhou Biotest Biotech Co.Ltd(688767) , Guangzhou Wondfo Biotech Co.Ltd(300482) , Beijing Wantai Biological Pharmacy Enterprise Co.Ltd(603392) responded that the company always pays attention to the global epidemic situation, promotes the overseas registration of covid-19 detection products, and the registration of covid-19 antigen detection products in the U.S. FDA is progressing in an orderly manner.
China Securities Journal · China Securities Taurus reporter noted that recently, a number of Companies in the covid-19 testing sector frequently issued stock price change announcements. Among them, Andon Health Co.Ltd(002432) and Hangzhou Biotest Biotech Co.Ltd(688767) two companies have announced changes since January 12, 2022. It is pointed out that the market competition of covid-19 testing products is fierce, and the sales and profit contribution of related products are uncertain, prompting investors to pay attention to risks.
